BCAB BioAtla Inc

$BCAB what a fraud.. only idiots keep there shares. And totally idiots buy. There are no value here. The one telling you that. Is the one who wan't to sell. Marked cap lower then a value of apartment tell you all you need to know

$BCAB looks to have an oral presentation at PEGS Europe on Nov 17 on its EpCAM program? Been a year since last update and many patients were still on treatment or just started. It's what got market excited for a second

$BCAB And most decisively, the research team that played a central role in the company's asset research has already left the company. Shareholders can't do anything. Other than paying J's salary and redirecting assets to the Himalayas...

$BCAB One thing I find particularly interesting on the Inversagen AI website is this comment. "Lloyd's of London has agreed to insure clinical trials on the strength of the same risk analysis." I have actually never seen this in any of the clinical stage biotechs I have followed. So I guess that whoever funds this trial has very little risk. Am I seeing this right? Lloyd's actually pays back the financer if the clinical trial fails? Weird. Cool, but weird.🤔

$BCAB if they do a deal by EOY, as the filing/new website suggests, probably 5-10x upside from here depending on how much they get for Oz-V. $2M market cap and last year were supposed to get $40M upfront for 35% of the drug, so over $100M valuation for Oz-V alone

$BCAB Tungsten was involved with today's $BOLT merger. Going to see something happen here very soon. Lots of upside if they sell their assets or merge into Inversagen.ai

$BCAB Most importantly, BP is not interested in the assets held by BCAB. Many companies that attempted CTLA4, such as LSTA, have been unable to sell their assets. Meanwhile, melanoma is now focusing on Moderna’s mRNA vaccine, and other assets represent only a niche market. You can't do anything with just a simple single-arm long tail. Because it is unattractive, they are ultimately forced to turn to predatory lenders like Yorkville.

$BCAB entered a $40 million standby equity purchase agreement with Yorkville, paying a $500K commitment fee.

$BCAB what are the latest proposed exec bonuses for driving this into the ground? Bonuses for bankruptcy, hilarious incentive plan.

$BCAB A cash performance bonus, contingent on the achievement of specific financial and capital-raising milestones, has been approved through March 31, 2027, to encourage the remainder of 2026 and first-quarter 2027 results. A scheme to swindle money again

$BCAB Tungsten added the Yorkville-BCAB financing to their web page. This doesn't seem to be acting as a company that is about to file for BK. If the stock climbed to $10 on any news of an asset sale, it would still only have an $8.5M market cap. And yes, at that time, the company should be deploying the SEPA. They had one for $15M so increasing it $40M does seem like they are preparing for something. With only 1.7M shares, they should be preparing to deploy the SEPA if this thing runs to $20-30/sh. Even at $30/eh, that's a $45M market cap for a bio tech with a Phase III drug on standby. That drug alone should be worth $45M, let alone the CAB platform. But hey, they market isn't seeing it that way.....for now....

$BCAB do it hurt in your behind..? Jay is pushing it up slowly on you guys. You will lose all. And Jay will keep on smiling and pull it out of you..